Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049385 | 0.96 | CYP3A4 (0.44) | NAAAALDH1A1ATMCYP3A4DGKA | |
| SCHEMBL2349921 | 0.93 | NAAA (0.56) | NAAADGKATSHRRAD52NPSR1 | |
| SCHEMBL2357450 | 0.93 | NAAA (0.56) | NAAADGKATSHRRAD52NPSR1 | |
| SCHEMBL2352860 | 0.93 | NAAA (0.56) | NAAADGKATSHRRAD52NPSR1 | |
| SCHEMBL15438827 | 0.92 | NAAA (0.44) | NAAADGKATSHRRAD52NPSR1 | |
| SCHEMBL15437991 | 0.92 | TSHR (0.43) | NAAAALDH1A1DGKATSHRPPARD | |
| SCHEMBL2238085 | 0.91 | CYP3A4 (0.48) | NAAAALDH1A1ATMCYP3A4DGKA | |
| SCHEMBL2044739 | 0.90 | NAAA (0.53) | NAAADGKARAD52NPSR1FAAH | |
| SCHEMBL2043579 | 0.90 | NAAA (0.53) | NAAADGKARAD52NPSR1FAAH | |
| SCHEMBL2049714 | 0.90 | NAAA (0.53) | NAAADGKARAD52NPSR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543875-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | Sitryx Therapeutics Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| EP-4030524-B1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4318719-A2 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023247958-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-28 | — | — | WO | disclosed |
| US-20230343990-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11784342-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4192821-A1 | ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2023-06-14 | — | — | EP | disclosed |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6137002-A | USEFUL FOR PREVENTION OF THROMBOSIS; FOR TREATING ATHEROSCLEROSIS AND ARTERIOSCLEROSIS, ACUTE MYOCARDIAL INFARCTION, CHRONIC STABLE ANGINA, UNSTABLE ANGINA, TRANSIENT ISCHEMIC ATTACKS AND STROKES, PERIPHERAL VASCULAR DISEASE, | ELI LILLY AND COMPANY (US) | 2000-10-24 | — | — | US | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5618843-A | INHIBIT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0635492-A1 | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
| US-4130659-A | Polyprenyl carboxylic acid compound and hypotensive agent containing it as active ingredient | EISAI CO., LTD. (JP) | 1978-12-19 | — | — | US | disclosed |
| US-4107193-A | HYPOTENSIVE | EISAI CO., LTD. (JP) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | SI, FABP2, ALPI | NAAA 1226/4885ALDH1A1 1040/4885ATM 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.